PDCD1 and classic Hodgkin lymphoma: The PD-1 inhibitors, nivolumab and pembrolizumab, were approved by the United States Food and Drug Administration (FDA) in 2016 and 2017, respectively, as therapies for transplant-ineligible R/R CHL patients [21].